BeOne Medicines: Waldenstrom Macroglobulinemia trials

The registry lists 10 Waldenstrom Macroglobulinemia studies with BeOne Medicines as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 6Phase 3 1Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaRecruitingNCT05640102
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
• A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
• Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)CompletedNCT03332173Phase 2Results posted
• A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)CompletedNCT03053440Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaActive, not recruitingNCT07169331Phase 4
• A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingNCT05952037Phase 2
• Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
• Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
• A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell MalignanciesNo longer availableNCT04052854